SCHEMBL60773

SCHEMBL60773

[CH2]C(C)C(CC)CCC

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27489860 0.97 LMNA (0.37)
SCHEMBL15519198 0.88 TSHR (0.36)
SCHEMBL28212463 0.85 TSHR (0.35)
SCHEMBL17607516 0.83 LMNA (0.36)
SCHEMBL1974135 0.83 ALDH1A1 (0.37)
SCHEMBL1971485 0.81 OPRM1 (0.44)
SCHEMBL17607514 0.81 LMNA (0.34)
SCHEMBL27448231 0.81 ALDH1A1 (0.36)
SCHEMBL59968 0.81
SCHEMBL11244836 0.80 TRPM8 (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 2990 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2006065842-A2 5,6,7,8-TETRAHYDROQUINOLINES AND RELATED COMPOUNDS AND USES THEREOF SYNTA PHARMACEUTICALS CORP. (US) 2006-06-22 WO claimed
EP-1663227-A2 DIHYDROPYRIDINE COMPOUNDS FOR TREATING OR PREVENTING METABOLIC DISORDERS Synta Pharmaceuticals Corporation (US) 2006-06-07 EP claimed
US-20050203119-A1 Dihydropyridine compounds for treating or preventing metabolic disorders SYNTA PHARMACEUTICAL CORP. 2005-09-15 US claimed
WO-2005025507-A2 DIHYDROPYRIDINE COMPOUNDS FOR TREATING OR PREVENTING METABOLIC DISORDERS SYNTA PHAMACEUTICALS CORP. (US) 2005-03-24 WO claimed
CN-118344364-A Amino-substituted fused heteroaryl compounds, preparation method thereof and application thereof in medicine 江苏恒瑞医药股份有限公司 2024-07-16 CN disclosed
CN-118344325-A PI3K selective inhibitors 轩竹生物科技股份有限公司 2024-07-16 CN disclosed
CN-113521299-B Pyrazolopyrimidine derivative or conjugate thereof, preparation method and application thereof 江苏恒瑞医药股份有限公司 2024-07-16 CN disclosed
CN-118344365-A Condensed heteroaryl compound, preparation method and medical application thereof 江苏恒瑞医药股份有限公司 2024-07-16 CN disclosed
CN-113939516-B Methods and compositions for targeting protein degradation 珃诺生物医药科技(杭州)有限公司 2024-07-16 CN disclosed
CN-114845739-B Pharmaceutical conjugate of eribulin derivative, preparation method and application thereof in medicine 上海森辉医药有限公司 2024-07-16 CN disclosed
CN-118339157-A Hydroindole compound, preparation method and medical application thereof 江苏恒瑞医药股份有限公司 2024-07-12 CN disclosed
CN-118324761-A USP inhibitor, preparation method and application thereof 北京华森英诺生物科技有限公司 2024-07-12 CN disclosed
CN-1040196-A Use of imidazopyrazole derivatives as analgesics and anti-inflammatory agents SANKYO CO (JP) 1990-03-07 CN disclosed
EP-0353047-A2 Use of imidazopyrazole derivatives as analgesics and anti-inflammatory agents Sankyo Company Limited (JP) 1990-01-31 EP disclosed
EP-0350315-A1 Rhizoxin derivates and their use as anti-tumor agents SANKYO COMPANY LIMITED (JP) 1990-01-10 EP disclosed
US-4791128-A Rhizoxin esters and salts, their pharmaceutical use as anti-tumor agents SANKYO COMPANY LIMITED (JP) 1988-12-13 US disclosed
US-4683224-A INSECTICIDES, MITICIDES, NEMATOCIDES E. I. DU PONT DE NEMOURS AND COMPANY (US) 1987-07-28 US disclosed
CN-86106331-A N-formyl radical sulfo-phosphonic amide ester 1987-06-03 CN disclosed
EP-0218310-A2 Rhizoxin derivatives, their preparation and pharmaceutical use SANKYO COMPANY LIMITED (JP) 1987-04-15 EP disclosed
CN-86102020-A The preparation method of rhizoxin derivatives and in pharmaceutically application 1986-10-01 CN disclosed